Risk factors for venous thromboembolism in children

International Angiology

Volumn 23, Issue 3, 2004, Pages 195-205

  Gerotziafas, Grigoris T ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

Child; Risk factors; Thromboembolism, prevention and control; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ASPARAGINASE; BLOOD CLOTTING FACTOR 5 LEIDEN; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISONE; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLOOD CLOTTING; CARDIOVASCULAR RISK; CENTRAL VENOUS CATHETERIZATION; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CLINICAL TRIAL; CRANIOTOMY; CRITICAL ILLNESS; CUSHING SYNDROME; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GENETIC RISK; HEMOSTASIS; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; INCIDENCE; LAPAROTOMY; METABOLIC DISORDER; MORBIDITY; NEPHROTIC SYNDROME; PREVALENCE; PROPHYLAXIS; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK FACTOR; SICKLE CELL ANEMIA; STROKE; SUBSTITUTION THERAPY; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTINEOPLASTIC AGENTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION; CATHETERIZATION, CENTRAL VENOUS; CEREBROVASCULAR ACCIDENT; CHILD; CHILD, PRESCHOOL; CRITICAL ILLNESS; CUSHING SYNDROME; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASMS; NEPHROTIC SYNDROME; RISK FACTORS; THROMBIN; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS; WOUNDS AND INJURIES;

EID: 11944271447     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Male C, Johnston M, Sparling C, Brooker L, Andrew M, Massicotte P. The influence of developmental haemostasis on the laboratory diagnosis and management of haemostatic disorders during infancy and childhood. Clin Lab Med 1999;19:39-69.
2. Kuhle S, Male C, Mitchel L. Developmental hemostasis: pro and anticoagulant system during childhood. Semin Thromb Haemost 2003;26:329-37.
3. Andrew M, Paes B, Ruth M, Johnston M, Mitchell L, Tollefsen DM et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-72.
4. Andrew M, Paes B, Milner R, Johnston M, Michell L, Tollefsen DM et al. Development of the human coagulation system in healthy premature infant. Blood 1988;72: 1651-7.
5. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of haemostatic system in childhood. Blood 1992;80:1998-2005.
6. Andrew M, Schmidt B, Mitchell L, Paes B, Ofosu F. Thrombin generation in new born plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990;63:27-30.
7. Heit JA, Melton LJ 3rd, Lohse CM, Petterson TM, Silverstein MD, Mohr DN et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 2001;76:1102-10.
8. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251-7.
9. Van Ommen CH, Heijboer H, Buller H, Hirasing RA, Heijmans HAS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139:676-81.
10. Bokenkamp A, von Kries R, Nowak-Gottl U, Gobel U, Hoyer PF. Neonatal renal venous thrombosis in Germany between 1992 and 1994: epidemiology, treatment and outcome. Eur J Pediatr 2000;159:44-8.
11. Monagle P, Adams M, Mahoney M, Ali K, Barnard D, Bernstein M et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000;47:763-6.
12. van Ommen CH, Heijboer H, van den Dool EJ, Hutten BA, Peters M. Pediatric venous thromboembolic disease in one single center: congenital prothrombotic disorders and the clinical outcome. J Thromb Haemost 2003;1: 2516-22.
13. Revel-Vilk S, Chan A, Bauman M, Massicotte P. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost 2003;1:915-21.
14. Tormene D, Simioni P, Prandoni P, Franz F, Zerbinati P, Tognin G et al. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study. Blood 2002;100:2403-5.
15. Bonduel M, Hepner M, Sciuccati G, Pieroni G, Feliu-Torres A, Mardaraz C et al. Factor V Leiden and prothrombin gene G20210A mutation in children with venous thromboembolism. Thromb Haemost 2002;87:972-7.
16. Atalay S, Akar N, Tutar HE, Yilmaz E. Factor V 1691 GA mutation in children with intracardiac thrombosis: a prospective study. Acta Paediatr 2002;91:168-71.
17. Kosch A, Junker R, Kurnik K, Schobess R, Gunther G, Koch H et al. Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. Thromb Res 2000;99:531-7.
18. Bonduel M, Hepner M, Sciuccati G, Torres AF, Pieroni G, Frontroth JP. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatr Hematol Oncol 2000;22:66-72.
19. Koch HG, Nabel P, Junker R, Auberger K, Schobess R, Homberger A et al. The 677T genotype of the common MTHFR thermolabile variant and fasting homocysteine in childhood venous thrombosis. Eur J Pediatr 1999;158 Suppl 3:S113-6.
20. Munchow N, Kosch A, Schobess R, Junker R, Auberger K, Nowak-Gottl U. Role of genetic prothrombotic risk factors in childhood caval vein thrombosis. Eur J Pediatr 1999;158 Suppl 3:S109-12.
21. Schobess R, Junker R, Auberger K, Munchow N, Burdach S, Nowak-Gottl U. Factor V G1691A and prothrombin G20210A in childhood spontaneous venous thrombosis: evidence of an age-dependent thrombotic onset in carriers of factor V G1691A and prothrombin G20210A mutation. Eur J Pediatr 1999;158 Suppl 3:S105-8.
22. Young G, Manco-Johnson M, Gill JC, Dimichele DM, Tarantino MD, Abshire T et al. Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study. J Thromb Haemost 2003;1:958-62.
23. Nowak-Gottl U, Vielhaber H, Grohmann J, Schneppenheim R, Koch HG. Arginine506 to glutamin mutation in the factor V gene in infancy and childhood: evidence of fibrinolytic impairment. Eur J Pediatr 1997;156:195-8.
24. Nowak-Gottl U, Vielhaber H. Elevated levels of soluble thrombomodulin in plasma from children with Arg 506 to Gln mutation in the factor V gene. Eur J Haematol 1997;58:51-5.
25. Nowak-Gottl U, Junker R, Kreuz W, von Eckardstein A, Kosch A, Nohe N et al. Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001;97:858-62.
26. Male C, Chait P, Ginsberg JS, Hanna K, Andrew M, Halton J et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 2002;87: 593-8.
27. Uszynski M, Osinska M, Zekanowska E, Ziolkowska E. Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes. Med Sci Monit 2000;6:108-11.
28. Mitchell L, Hoogendoorn H, Giles AR, Vegh P, Andrew M. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L-Asparaginase-induced antithrombin III deficiency Blood 1994;83:386-91.
29. Korte W, Feldges A, Baumgartner C, Ullmann S, Niederer V, Schmid L. Increased thrombin generation during fibrinogen and platelet recovery as an explanation for hypercoagulability in children with L-asparaginase therapy for ALL or NHL: a preliminary report. Klin Padiatr 1994;206:331-3.
30. Nowak-Gottl U, Kuhn N, Wolff JE, Boos J, Kehrel B, Rath B et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children. Eur J Haematol 1996;56:35-8.
31. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003;90:235-44.
32. Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora KW. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999;158 Suppl 3:S143-6.
33. Mauz-Korholz C, Nurnberger W, Irsfeld H, Korholz D, Gobel U. Low rate of severe venous thromboses in children with ALL treatment according to COALL-92 and -97 protocol. Klin Padiatr 1999;211:215-7.
34. Giordano P, Del Vecchio GC, Santoro N, Arcamone G, Coppola B, Altomare M et al. Thrombin generation in children with acute lymphoblastic leukemia: effect of leukemia immunophenotypic subgroups. Pediatr Hematol Oncol 2000;17:667-72.
35. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003;111: 199-212.
36. Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001;103:165-72.
37. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr 1998;133:770-6.
38. Fratino G, Mazzola C, Buffa P, Torre M, Castagnola E, Magillo P et al. Mechanical complications related to indwelling central venous catheter in pediatric hematology/oncology patients. Pediatr Hematol Oncol 2001;18: 317-24.
39. Worly JM, Fortenberry JD, Hansen I, Chambliss CR, Stockwell J. Deep venous thrombosis in children with diabetic ketoacidosis and femoral central venous catheters. Pediatrics 2004;113:57-60.
40. Gutierrez JA, Bagatell R, Samson MP, Theodorou AA, Berg RA. Femoral central venous catheter-associated deep venous thrombosis in children with diabetic ketoacidosis. Crit Care Med 2003;31:80-3.
41. Ruud E, Holmstrom H, Natvig S, Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer: a prospective study. Med Pediatr Oncol 2002;38:405-10.
42. Beck C, Dubois J, Grignon A, Lacroix J, David M. Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J Pediatr 1998;133:237-41.
43. Shah JK, Mitchell LG, Paes B, Ofosu FA, Schmidt B, Andrew M. Thrombin inhibition is impaired in plasma of sick neonates Pediatr Res 1992;31:391-5.
44. Balakrishnan G, Brownlie J, Webber R, Gibson B. Enhanced thrombin generation in patients receiving intensive care. Arch Dis Child 1991;66:1413-5.
45. Brus F, Van Oeveren W, Okken A, Oetomo SB. Disease severity is correlated with plasma clotting and fibrinolytic and kinin-kallikrein activity in neonatal respiratory distress syndrome. Pediatr Res 1997;41:120-7.
46. Brandtzaeg P, Bjerre A, Ovstebo R, Brusletto B, Joo GB, Kierulf P. Neisseria meningitidis lipopolysaccharides in human pathology. J Endotoxin Res 2001;7:401-20.
47. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000;95:930-5.
48. Setty BN, Kulkarni S, Rao AK, Stuart MJ. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood 2000;96:1119-24.
49. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001;98:3228-33.
50. Liesner R, Mackie I, Cookson J, McDonald S, Chitolie A, Donohoe S et al. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol 1998;103:1037-44.
51. Peters M, Plaat BE, ten Cate H, Wolters HJ, Weening RS, Brandjes DP. Enhanced thrombin generation in children with sickle cell disease. Thromb Haemost 1994;71:169-72.
52. Bayazit AK, Kilinc Y. Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int 2001;43:592-6.
53. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA et al. In vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol 1997;98: 51-6.
54. Campos LM, Kiss MH, D'Amico EA, Silva CA. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus 2003;12:820-6.
55. Albisetti M, Chan AK, McCrindle BW, Wong D, Vegh P, Adams M et al. Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease. Blood Coagul Fibrinolysis 2003;14:181-6.
56. Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001;97:844-9.
57. Male C, Lechner K, Eichinger S, Kyrle PA, Kapiotis S, Wank H et al. Clinical significance of lupus anticoagulants in children. J Pediatr 1999;134:199-205.
58. Cario H, Pahl HL, Schwarz K, Galm C, Hoffmann M, Burdelski M et al. Familial polycythemia vera with Budd-Chiari syndrome in childhood. Br J Haematol 2003;123: 346-52.
59. Khubchandani RP, D'Souza S. Antiphospholipid antibody syndrome as a cause of Budd-Chiari syndrome. Indian Pediatr 2003;40:907-8.
60. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002;346:23-32.
61. Nevard CH, Jurd KM, Lane DA, Philippou H, Haycock GB, Hunt BJ. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 1997;78:1450-5.
62. Thayu M, Chandler WL, Jelacic S, Gordon CA, Rosenthal GL, Tarr PI. Cardiac ischemia during hemolytic uremic syndrome. Pediatr Nephrol 2003;18:286-9.
63. Schlegel N. Thromboembolic risks and complications in nephrotic children. Semin Thromb Hemost 1997;23:271-80.
64. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 2000;23:145-50.
65. Vavilala MS, Nathens AB, Jurkovich GJ, Mackenzie E, Rivara FP. Risk factors for venous thromboembolism in pediatric trauma. J Trauma 2002;52:922-7.
66. Lanari M, Lazzarotto T, Papa I, Venturi V, Bronzetti G, Guerra B et al. Neonatal aortic arch thrombosis as a result of congenital cytomegalovirus infection. Pediatrics 2001;108:E114.
67. deVeber G. Arterial ischemic strokes in infants and children: an overview of current approaches. Semin Thromb Hemost 2003;29:567-73.
68. Chan AK, Deveber G, Monagle P, Brooker LA, Massicotte PM. Venous thrombosis in children. J Thromb Haemost 2003;1:1443-55.